TL;DR
Get comfort and care essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
Physician Hana Kahleova argues that clinical antibiotic stewardship misses a major source of drug resistance: routine antibiotic use in food animals. She cites the decline in colistin resistance after China banned its use as a feed additive, while calling for targeted farm policies and changes in institutional purchasing and food demand.
In an October 4 opinion article, physician Hana Kahleova argues that clinicians treating drug-resistant infections should pay more attention to antibiotic use in food animals, not just prescribing in hospitals and clinics. She points to China’s 2017 ban on colistin as a feed additive, followed by measured declines in resistance in animals and people, as evidence that changes in farm policy can affect a drug important to human medicine.
Kahleova writes that about 70% of antibiotics considered important to human medicine in the United States are sold for use in food animals. She says much of that use is not to treat sick livestock, but to prevent illness among healthy animals raised in crowded conditions. The figure and explanation are presented in her opinion article; the supplied material does not provide the underlying study or sales data.
The article describes how resistance can move beyond farms through meat, water, dust, workers and manure, eventually appearing in patient cultures. Kahleova also cites projections that livestock antibiotic use could rise by nearly a third by 2040, an estimate of about 35,000 U.S. deaths annually from resistant infections, and a Lancet forecast of roughly 39 million deaths worldwide from resistant infections between now and 2050. These are estimates and forecasts, not counts of deaths already observed over those future periods.
As a policy example, she discusses mcr-1, a transferable gene associated with colistin resistance. The gene emerged amid colistin use as a growth promoter on Chinese pig farms and spread internationally, according to the article. After China prohibited colistin as a feed additive in 2017, resistance reportedly fell in animals and people. The article characterizes this as a real-world policy result; it does not supply the underlying measurements or study details.
Why Farm Antibiotic Use Matters
The argument shifts part of the stewardship discussion upstream of the clinic. Doctors can choose antibiotics carefully for individual patients, but they have little control over how drugs are used across food production. If routine use in livestock contributes to resistance that later reaches people, clinical prescribing controls alone may not address the full source of the problem.
Kahleova does not call for ending veterinary antibiotics. She says sick animals still need treatment and frames the policy goal as stopping routine preventive use in animals that are not ill. She also points to actions available to health institutions and clinicians, including reviewing food-service purchasing and discussing more plant-forward diets. Those actions, she argues, can complement farm regulation but cannot replace it.
As an affiliate, we earn on qualifying purchases.
The Colistin Policy Example
Colistin is used as a last-resort antibiotic for some infections resistant to other drugs. Its use as a growth promoter in Chinese pig production became a concern after the transferable mcr-1 resistance gene was identified and spread beyond China. The article presents the 2017 feed-additive ban as a case in which restricting agricultural use was followed by reduced resistance in animals and people.
The World Health Organization has urged farmers to stop routine preventive antibiotic use in animals that are not sick, Kahleova notes. That position is distinct from eliminating veterinary treatment. Her article argues that health systems’ stewardship efforts often focus on prescribing practices while giving less attention to agricultural use and the demand for meat produced in confinement systems.
Evidence and Scale Still Need Detail
The supplied article does not include the studies, datasets or methods behind its 70% U.S. antibiotic-use figure, the projected rise in livestock use, or the reported declines in resistance after China’s ban. The specific size and timing of those declines, and how much of the change can be attributed to the policy rather than other factors, are not detailed in the material provided.
The article also does not quantify how much resistance in U.S. patients can be traced to livestock use, compared with other sources such as human antibiotic use. Its global death projection is a forecast through 2050, not a prediction tied to a single cause. The scale of any effect from dietary choices or institutional purchasing is also not established in the article.
Policy and Health-System Responses
Kahleova calls on clinicians to press professional societies for targeted farm-level policies that limit routine preventive antibiotic use while preserving treatment for sick animals. She also urges health institutions to review food-service contracts and clinicians to discuss how food choices relate to demand for animal products raised in confinement systems.
The opinion article does not announce a new regulation, institutional policy or clinical guideline. The next developments to watch are whether professional groups or health systems adopt the measures she proposes, and whether governments expand restrictions on routine agricultural antibiotic use. Further evidence would also be needed to measure the effect of those steps on resistance in animals and people.
Key Questions
What is the main argument of the article?
Hana Kahleova argues that antibiotic stewardship should include food-animal production, since routine use in livestock may contribute to resistance that later affects human patients.
Does the article call for banning all antibiotics in animals?
No. Kahleova says animals that are genuinely sick still need treatment. Her argument focuses on routine preventive use in animals that are not ill.
What happened with colistin in China?
The article says China banned colistin as a feed additive in 2017, after its use in pig farming was associated with the spread of the mcr-1 resistance gene. Kahleova reports that resistance later fell in animals and people, but the supplied material does not include the underlying measurements.
How much antibiotic use in the United States is for food animals?
Kahleova cites an estimate that about 70% of antibiotics important to human medicine in the United States are sold for use in food animals. The opinion article does not provide the source data or its methodology.
What remains uncertain about the claims?
The supplied material does not establish the precise contribution of livestock antibiotic use to resistant infections in U.S. patients, or quantify the effects of proposed changes to diets and institutional purchasing. The article’s figures and the reported post-ban declines require the underlying studies for fuller assessment.
Source: rss
Cold & flu season Picks
humidifiers
As an affiliate, we earn on qualifying purchases.
